Published in J Clin Aesthet Dermatol on June 01, 2010
The grape antioxidant resveratrol for skin disorders: promise, prospects, and challenges. Arch Biochem Biophys (2011) 0.88
Evaluation of the skin sensitization, photoirritation, and photoallergic potential of ingenol mebutate gel in healthy volunteers. J Clin Aesthet Dermatol (2014) 0.83
Histopathological analysis of the therapeutic response to cryotherapy with liquid nitrogen in patients with multiple actinic keratosis. An Bras Dermatol (2015) 0.81
Current and emerging treatment strategies for the treatment of actinic keratosis. Clin Cosmet Investig Dermatol (2010) 0.81
The role of ingenol mebutate in the treatment of actinic keratoses. Dermatol Ther (Heidelb) (2012) 0.80
A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol (2015) 0.80
Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. J Clin Aesthet Dermatol (2014) 0.79
Cost-utility of first-line actinic keratosis treatments in Finland. Adv Ther (2015) 0.78
Development of nanovesicular systems for dermal imiquimod delivery: physicochemical characterization and in vitro/in vivo evaluation. J Mater Sci Mater Med (2015) 0.75
Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate. PLoS One (2016) 0.75
Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis. Dermatol Ther (Heidelb) (2017) 0.75
Cutaneous squamous-cell carcinoma. N Engl J Med (2001) 7.31
Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol (2002) 3.20
Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol (2000) 2.23
Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med (1988) 2.03
Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol (1986) 1.99
Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet (1988) 1.82
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
Prevention of skin cancer and reduction of keratotic skin lesions during acitretin therapy in renal transplant recipients: a double-blind, placebo-controlled study. J Clin Oncol (1995) 1.13
Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer (1997) 1.13
Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol (1998) 1.11
Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev (2000) 1.09
Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. Recent Results Cancer Res (2002) 1.08
Frequency and cost of actinic keratosis treatment. Dermatol Surg (2006) 1.07
Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Arch Dermatol (2006) 1.07
Actinic keratosis. Int J Dermatol (2007) 1.06
Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol (2005) 1.04
Chemoprevention of human skin cancer. Crit Rev Oncol Hematol (2002) 1.04
Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev (1997) 1.02
Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol (1991) 1.02
Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation (2004) 1.02
The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg (2002) 1.02
The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol (2004) 1.00
Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract (2006) 0.98
Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. J Invest Dermatol (2007) 0.97
Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol (2006) 0.93
A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999. National Ambulatory Medical Care Survey. Cutis (2002) 0.92
Topical thymidine dinucleotide treatment reduces development of ultraviolet-induced basal cell carcinoma in Ptch-1+/- mice. Am J Pathol (2008) 0.92
Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol (2005) 0.92
Localization of liposomes containing a DNA repair enzyme in murine skin. J Invest Dermatol (1994) 0.89
Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol (2009) 0.89
Topical treatment with liposomes containing T4 endonuclease V protects human skin in vivo from ultraviolet-induced upregulation of interleukin-10 and tumor necrosis factor-alpha. J Invest Dermatol (2000) 0.88
The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg (2007) 0.88
Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant (2005) 0.86
Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. J Invest Dermatol (2006) 0.86
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol (2004) 0.85
PDT as a cytotoxic agent and biological response modifier: Implications for cancer prevention and treatment in immunosuppressed and immunocompetent patients. J Invest Dermatol (2006) 0.84
Low-dose retinoid therapy for chemoprophylaxis of skin cancer in renal transplant recipients. J Eur Acad Dermatol Venereol (1998) 0.81
Acitretin suppression of squamous cell carcinoma: case report and literature review. J Dermatolog Treat (2003) 0.81
Treatment options in the management of actinic keratosis. Cutis (2004) 0.78
Infiltrative basal cell carcinomas presenting as actinic keratosis: implications for clinical practice. Dermatol Surg (2007) 0.77
Topical tretinoin in actinic keratosis and basal cell carcinoma. J Am Acad Dermatol (1986) 0.77
Practical retinoid chemoprophylaxis in solid organ transplant recipients. Dermatol Ther (2005) 0.76